|
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study.
|
22016816 |
2011 |
|
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy.
|
24841650 |
2014 |
|
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conclude that ABCC3 rs4148416 polymorphism was significantly associated with poor osteosarcoma response and ABCB1 rs1128503 polymorphism was significantly associated with good osteosarcoma response in Caucasian population rather than Asian population.
|
26107220 |
2015 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The overexpression of the ezrin deletion mutant entirely restored drug susceptibility of osteosarcoma cells, consistent with Pgp dislocation to cytoplasmic compartments and abrogation of G(M1) /Pgp co-localization at the plasma membrane.
|
21780101 |
2012 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, based on our previous study, we further identified that the lncRNA FOXC2-AS1 and its antisense transcript FOXC2 are positively up-regulated in doxorubicin-resistant osteosarcoma cell lines and tissues, correlate with poor prognosis and promote doxorubicin resistance in osteosarcoma cells in vitro and in vivo.
|
28323030 |
2017 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, we concluded that lncRNA ODRUL may act as a pro-doxorubicin-resistant molecule through inducing the expression of the classical multidrug resistance-related ABCB1 gene in osteosarcoma cells .These findings may provide a novel target for reversing doxorubicin resistance in OS.
|
26408180 |
2016 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Improving the cytometric detection of doxorubicin resistance in osteosarcoma cells by determining cellular doxorubicin/DNA ratio.
|
10697541 |
2000 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Reversion of P-glycoprotein-mediated multidrug resistance by diallyl trisulfide in a human osteosarcoma cell line.
|
24788927 |
2014 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, it was concluded that LIMK1 serves a key role in the MDR of osteosarcoma and functions through MDR1.
|
29387219 |
2018 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of doxorubicin-resistance is the main difficulty for osteosarcoma treatment.
|
30974157 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The levels of ROR, miR-153-3p, and ABCB1 in cisplatin-resistant OS tissues and cells were detected by qRT-PCR and/or Western blot assay.
|
31539112 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, RA is a promising potential therapeutic for the treatment of doxorubicin resistance in OS.
|
30745853 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we analyzed the subcellular localization of P-glycoprotein, in a series of U-2 OS osteosarcoma cell clones transfected with MDR1 gene in order to verify whether the nucleus is a constant site for the localization and functional activity of P-glycoprotein, and in which way some aspects of cell morphology related to MDR depend on the subcellular P-glycoprotein localization rather than on the exposure to the selective drug.
|
10321019 |
1999 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
A lncRNA-mRNA co-expression network identified lncRNAs, including ENST00000563280 and NR-036444, may play a critical role in doxorubicin-resistance of OS by interacting with important genes such as ABCB1, HIF1A and FOXC2.
|
26464619 |
2015 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intracellular pH regulation in U-2 OS human osteosarcoma cells transfected with P-glycoprotein.
|
11853886 |
2002 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, results indicate the vital role of LUCAT1 in the methotrexate resistance regulation through miR-200c/ABCB1 pathway, providing a novel insight and treatment strategy for osteosarcoma drug resistance.
|
29170124 |
2018 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1.
|
25727016 |
2015 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The goal of this study was to establish human FK228-resistant osteosarcoma cell lines and to investigate whether there are mechanisms of FK228 resistance in addition to P-gp up-regulation.
|
19073909 |
2009 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extracellular matrix induces doxorubicin-resistance in human osteosarcoma cells by suppression of p53 function.
|
17703109 |
2007 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
HA-Lsdox showed favorable drug-release profile and higher toxicity in vitro and in vivo than dox or the FDA-approved liposomal dox Caelyx<sup>®</sup> against Pgp-overexpressing osteosarcoma, displaying the same cardiotoxicity profile of Caelyx<sup>®</sup>.
|
31047947 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a previous study, we reported a novel lncRNA, ODRUL, that could promote doxorubicin resistance in OS.
|
28750740 |
2017 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fibronectin-1 modulated by the long noncoding RNA OIP5-AS1/miR-200b-3p axis contributes to doxorubicin resistance of osteosarcoma cells.
|
30204936 |
2019 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1.
|
27222034 |
2016 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, the results indicated that SNHG12 mediated doxorubicin resistance of osteosarcoma via miR-320a/MCL1 axis.
|
30119255 |
2018 |
|
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study determined if pioglitazone (PIO), a PPARγ agonist, could modulate P-gp and overcome doxorubicin (DOX)-resistance in a patient-derived orthotopic xenograft (PDOX) model of osteosarcoma.
|
31545293 |
2019 |